

Starpharma Holdings (SPL)

Starpharma Holdings soars 10.0% on robust volume

Starpharma Holdings Limited, Australia's 6th largest Pharmaceuticals, Biotechnology & Life Sciences company by market cap, soared 7.0c (or 10.0%) to close at 77.0c. Compared with the All Ordinaries Index which rose 45.5 points (or 0.8%) in the day, this represented a relative price increase of 9.2%. This has been propped up by robust volume of 2.1 times average.

Introduction

We are currently bullish on this stock in the short-term based on technical indicators, but are more bearish in the long-term based on fundamental metrics

What makes us most bullish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are rising, with its 12-day higher than its 26-day.
- The price to 200-day MAP ratio is 1.28, a bullish indicator.
- It has outperformed 80% of the market the past 6 months.
- The price to 50-day EMAP ratio is 1.4, a bullish indicator. The 50-day EMAP has increased to 54.85c.

However, there are some reasons why we remain bearish on the stock for the long-term:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 6.7. Compared with the rest of the market the stock is overvalued and ranks in the bottom 6% of stocks by value of Q Ratio.

Stock Summary

Day's Range	69.50c-77.50c
52-Week Range	41.0c-98.50c
Today's Turnover	\$764,823
Relative Strength	80
Sector	Pharmaceuticals, biotechnology & life sciences
Volume	993,277
Volume Index (1 is avg)	2.1
Market Cap	\$245.7 million
Shares Outstanding	319,138,501
ISIN	AU000000SPL0

Financial Summary

Year ended	Jun 2014	Jun 2013	Jun 2012
Sales (AUDm)	1.2	2.2	3
Pretax (AUDm)	(13.8)	(4.8)	(14)
Net (AUDm)	(13.8)	(4.8)	(14)
EPS (AUD)	(0.05)	(0.02)	(0.05)

MCap: A Historical Perspective

	Share Price (AUD)	Market Cap (\$)
Last	0.8	194.4 million
1 Year ago	0.7	174.9 million
2 Years ago	0.9	265.1 million
3 Years ago	1.8	506.5 million
4 Years ago	1.4	422.5 million
5 Years ago	0.6	144.7 million

Analysis

Bullish Signals

- The price is at a premium of 28.3% to the 1-month volume weighted average price of 60.0c.

Volume Weighted Price



- The price soared 62.1% in the last month. This was on volume of 1.1 times average for month.
- In the Australian market of 1,156 stocks and 55 units traded today, the stock has a 6-month relative strength of 80 indicating it has outperformed 80% of the market.
- Also, the relative strength percentile is rising at 80 for 6 months, 89 for 3 months and 97 for 1 month.
- The price to 50-day EMAP ratio is 1.4, a bullish indicator. The 50-day EMAP has increased to 54.85c. An increase is another bullish indicator.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 0.65 minus the 26-day EMA of 0.59 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The Price/MAP of 1.28 for SPL is higher than the Price/MAP for the All Ordinaries Index of 1.0.
- The price to 200-day MAP ratio is 1.28, a bullish indicator. The stock is trading above both its MAPs and the 50-day MAP of 62.67c is higher than the 200-day MAP of 60.07c, a bullish indicator. The 200-day MAP has increased to 60.07c. An increase is another bullish indicator.
- The stock traded at a thirteen-month high of 77.50c today.

Other Bullish Signals:

Also, the following criteria set by Benjamin Graham:

- "Total debt less than tangible book value"; total debt of \$A75,000 is less than tangible book value of \$A25.2 Million.
- "Current ratio of two or more"; current assets are 7.4 times current liabilities.

Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price/MAP50	1.23	In Top 3%
Total Debt to Equity	0.002	In Top 4%
Price Change %	10.0	In Top 8%
Price/MAP200	1.28	In Top 8%
%Prem To Vol Wtd Price	28.3	In Top Quartile
Relative Strength (6M)	80	In Top Quartile
Today's Turnover	\$764,823	In Top Quartile

PRICE PERFORMANCE RANK IN INDICES AND SECTORS:

The stock is in 3 indices and 3 sectors.

The following index and sector rose, setting the trend for the stock's rise of 10.0%:

In today's trading:

The All Ordinaries Index [420 stocks and 44 units traded] was up 45.5 points or 0.8% to 5,673.

The Total Australian Market [1155 stocks and 55 units traded] was up 25.3 points or 0.5% to 5,054.

The stock's rise went against the trend set by the Pharmaceuticals, biotechnology & life sciences sector [57 stocks traded] was down 136.2 points or 1.2% to 11,535.

Price Percentile Rank and comparison:

Percentile Rank	1-day	1-month	6-months
SPL	94	97	80
Pharmaceuticals, biotechnology & life sciences	25	25	60
All Ordinaries Index	70	33	55

Analysis (continued)

Price/Moving Average Price [P/MAP]



Bearish Signals

- The price has risen above the upper Bollinger band of 76.29c; the Relative Strength Index (RSI) of 85.9 has penetrated the overbought line of 70; the stock is also overbought according to the Williams % R indicator of -1.7.

Overvaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 6.7. Compared with the rest of the market the stock is overvalued and ranks in the bottom 6% of stocks by value of Q Ratio.

Other Bearish Signals: Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Volatility %	11.5	In Bottom Quartile
Price to Book Value	9.8	In Bottom 8%

Note


Volatility

The stock traded between an intraday low of 69.50c and high of 77.50c. The price range has expanded in the last two days (from 6.0c two days ago to 8.0c today) which, accompanied by a price rise, is a bullish signal. Today its volatility of 11.5% was 3.9 times its average volatility of 3.0%. A price rise on high volatility is a bullish signal. The average daily volatility of 5.0% places the stock in the 2nd quartile in the market meaning it is moderately volatile.

Volume and turnover period


There were 993,277 shares worth \$764,823 traded. The volume was 2.1 times average trading of 468,585 shares. The turnover rate in the 12 months to date was 36.7% (or a turnover period of 2 years 8 months). This average length of ownership of the stock at 1 times the average holding period of 2 years 40 days for stocks in the All Ordinaries Index suggests a larger number of core investors, making a long-term investment safer.

Turnover Rate & Turnover Period



- It is at a discount of 21.8% to the 12-month high of 98.50c on 23 Jul, 2014. It is also at a premium of 87.8% to the 12-month low of 41.0c on 16 Dec, 2014.

Discount to High & Premium to Low



Beta & Standard Deviation (SD)

The Beta of this stock is 0.7. A Beta lower than 1 suggests this is a low risk, low return stock with volatility less than that of the market.

SD is a statistical measure of deviation from the mean. The SD of 3.4% gives it a percentile rank of 52 meaning that 52% of stocks in the Australian market are less volatile than this stock.


Analysis (continued)

The stock meets the following value criteria:


Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$194.4 million	In 2nd Quartile


YTD Comparison Stock Sector Index




Relative Strength



Present Value of \$1000 invested a year ago



% Growth Y.O.Y, Revenue & Net Profit



Rankings

Long-Term Fundamental Ranking: 2 out of 5

Starpharma Holdings is ranked number 6 out of 71 listed pharmaceuticals, biotechnology & life sciences companies [that traded today] in Australia with a market capitalization of \$245.7 million.

In the pharmaceuticals, biotechnology & life sciences companies it has the 13th highest total assets and 32nd highest revenues.




Stocks are scored on a set of parameters reflecting fundamental analytical tools involving valuation, size and financial performance. They are ranked according to the average values of those parameters. The highest ranking is 5 and the lowest ranking is 1.

Short-Term Technical Ranking: 5 out of 5

Its price change has been positive in the short-term over 5 days, medium-term over 3 months and over the period of 1 year. Its short term rises have been combined with strong volume resulting in strong momentum rises over 1 day. Significantly its price of 77.0c is at a premium of 28% to its 200-day moving average price of 60.07c. Its 52-week range has been 98.50c to 41.0c; it is trading at a discount of 21.8 % to its 52-week high and a premium of 87.8 % to its 52-week low. \$1,000 invested exactly one year ago is now worth \$1,176 of which \$176 is a capital gain.

Recommended stop loss: 71.23c



Stocks are scored on a set of technical parameters reflecting price performance and trading volumes. They are ranked according to the average values of those parameters. The highest ranking is 5 and the lowest ranking is 1.

BuySellSignals Fundamentals Valuation Table: Total Australian Market

	Total Australian Market	SPL	Rank	Rank 1	Rank 2	Rank 3	Lowest Rank
P/Earnings	20.2x		580	1.7x NWH	1.7x MRV	1.9x BXN	
Price/Net Tangible Assets	2.6x	9.8x	860	0.1x AUG	0.1x GBA	0.1x OVR	
Total Debt/Equity	0.5x	0.002x	13	AMA	0.001x MLX	0.001x ADA	9.04x UNS
Discount to 52-Wk High (%)	5.3	21.8	968	97.2 88E	96.7 IPB	96.7 DUO	0.3 JBH
Premium to 52-Wk Low (%)	13.01	87.8	1082	0.1 AYD	0.8 GZL	0.96 NHC	
Market Cap \$	1.6 B	245.7 M	358	172.7 B BHP	134.9 B CBA	110.1 B RIO	383,537 BMG
Revenue \$	682.6 M	1.3 M	945	88.7 B BHP	61.2 B WOW	60.6 B WES	
Free Cash Flow	54.5 million		1185	27.9 B WBC	11.9 B BHP	5.5 B FMG	

BuySellSignals Technical Valuation Table: Total Australian Market

	PV \$1,000 (1 Yr)	Rel Strength (6m)	PEMAP50	1-Day Price (%)	5-Day Price (%)	30-Day Price (%)	3-Month Price (%)	1-Year Price (%)	30-Day Avg Volatility	Momentum
Total Australian Market Avg	1,048.9	54.2	-	0.5	-2.2	-3.5	-0.5	4.9	2.01	-
SPL	1,175.6	79.5	1.4x	10	16.7	62.1	46.7	17.6	6.2	↑
Rank	412	244	15	50	61	35	123	383	283	63
Rank 1	17,000.0 ISX	99.9 3DM	3.7x PGI		100 PTR	207.7 DCC	900 GLF	1600 ISX	100 QFX	↑ GXN
Rank 2	9,000.0 ERJ	99.8 MTN	2.6x PTX		86.7 RTA	200 IGS	775 SHE	800 ERJ	57.1 IGS	↑ RTA
Rank 3	8,783.8 MIG	99.7 SHE	1.8x DCC		67.7 BRB	172.7 HHM	385.7 MTN	778.4 MIG	54.6 MMC	↑ MNQ

News and Events

Company Announcements: Recent Headlines and Snippets

February 16, 2015: Starpharma Holdings Limited: Interim Report and Half-Year Financial Results

Starpharma Holdings Limited reported loss of \$8.5M (Dec 2013: \$5.6M) Cash position at 31 December 2014 of \$39.3M R&D tax incentives of \$1.6M reported in the half-year (Dec 2013: \$2.6M) Receipt of \$4.2M R&D tax incentive refund \$20.5M net proceeds from equity placement and share purchase plan Operational Highlights: Launch of the VivaGelA condom in Australia by Starpharma's marketing partner, Ansell, under its LifestylesA Dual Protecta brand: product now on sale in Woolworths stores nationally Grant of FDA Special Protocol Assessment (SPA) for VivaGelA phase 3 trials Commencement of VivaGelA phase 3 trials for prevention of recurrent bacterial vaginosis DEPA docetaxel phase 1 trial approaching 50% recruitment with encouraging initial results Marketing clearance for the VivaGelA condom achieved in New Zealand Starpharma's PriostarA glyphosate patent allowed in China The net loss after tax of \$8.5 million (Dec 2013: \$5.6 million) includes expenses for the VivaGelA clinical program, together with development expenses in the drug delivery and agrochemical programs. Source: NBAFX **Open Full Announcement.**

January 30, 2015: Starpharma Holdings: Appendix 3B

[News Story]

<http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&id=01594602>

Source: Australian Securities Exchange **Open Full Announcement.**

January 22, 2015: Starpharma Holdings increases issued capital by 0.02%

Starpharma Holdings (SPL.AU) has announced an increase of 58,176 shares (or 0.02%) in total share on issue from 319,080,325 to 319,138,501. The effective date is 22 Jan, 2015. **Open Full Announcement.**

December 23, 2014: Starpharma Holdings increases issued capital by 0.01%

Starpharma Holdings (SPL.AU) has announced an increase of 22,000 shares (or 0.01%) in total share on issue from 319,058,325 to 319,080,325. The effective date is 23 Dec, 2014. **Open Full Announcement.**

December 17, 2014: Starpharma director buys on-market

Starpharma Holdings Ltd director Jacinth Fairley directly bought 100,000 shares on-market for \$43,447 on December 16, 2014. He directly holds 2,247,274 shares, 2,310,000 performance rights and indirectly holds 55,000 shares. **Open Full Announcement.**

December 17, 2014: Acorn sells 6.3m Starpharma shares

Acorn Capital Ltd sold 6,340,097 Starpharma Holdings Ltd shares between September 3 and December 16, 2014, decreasing from 25,054,351 shares (8%) to 18,714,254 shares (5.87%). **Open Full Announcement.**

December 05, 2014: Starpharma Holdings Announces Update on VivaGel Condom Launch Timing in Japan

Starpharma Holdings announced that the planned launch timing of the VivaGel condom in Japan would be delayed following a review of the specific category of medical device classification by the Japanese regulatory authorities. The regulatory status of the VivaGel condom in other regions where the product is approved for sale (Australia and NZ) or is undergoing regulatory review is not affected and does not rely upon the Japanese classification or approval process. **Open Full Announcement.**

December 04, 2014: Starpharma Holdings increases issued capital by 0.02%

Starpharma Holdings (SPL.AU) has announced an increase of 50,000 shares (or 0.02%) in total share on issue from 319,008,325 to 319,058,325. The effective date is 03 Dec, 2014. **Open Full Announcement.**

November 28, 2014: Starpharma Holdings Announces Marketing Clearance for VivaGel Condom in New Zealand

Starpharma Holdings announced the completion of the regulatory requirements to allow for marketing of the VivaGel condom in New Zealand under the brand Lifestyles Dual Protect. The Company's commercial partner, Ansell, along with their New Zealand distributor, EBOS Group, plan to launch the Lifestyles Dual Protect condom in the New Year having obtained market clearance for New Zealand. **Open Full Announcement.**

Company Overview

Activities

Starpharma Holdings Limited is biotechnology company involved in the research, development and commercialization of dendrimer-based for pharmaceutical, life sciences and other applications. The Company's lead product in development is VivaGel, a microbicide gel for women, for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases.

Industry Group	Pharmaceuticals
Industry	Pharmaceuticals
Economic Sector	Healthcare
Business Sector	Pharmaceuticals & Medical Research

Further details can be found at www.starpharma.com.


Issued Capital

Based on 319,138,501 issued equity shares the market capitalisation is \$245.7 million. It is Australia's 32nd largest Pharmaceuticals, biotechnology & life sciences company by total revenue.

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
HSBC Custody Nominees (Australia) Limited	50,475,546	15.82
National Nominees Limited	47,275,727	14.81
JP Morgan Nominees Australia Limited	29,807,573	9.34
Citicorp Nominees Pty Limited	12,003,655	3.76
JP Morgan Nominees Australia Limited (Cash Income A/C)	7,487,784	2.35
T And N Argyrides Investments P/L (Super Fund A/C)	5,500,799	1.72
Mr Peter Malcolm Colman	4,097,286	1.28
Kenneth Nominees Pty Ltd (Rayse Super Fund A/C)	4,040,000	1.27
Citicorp Nominees Pty Limited (Colonial First State Inv A/C)	3,513,029	1.1
JPS Distribution Pty Ltd (Raff Super Fund A/C)	3,249,511	1.02
Total	167,450,910	52.47

Top 20 Shareholders



Board and Management

Jackie Fairley CEO



Dr Jackie Fairley has more than 25 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. Jackie holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie is also a Graduate of the Australian Institute of Company Directors. Jackie currently sits on the board of the Melbourne Business School, is a member of the Commonwealth Science Council, and is a past member of the Federal Government's Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.

Robert Thomas Chairman & Non-Executive Director

Mr Thomas has a strong background in financial services and is a non executive director on a number of listed Healthcare companies in Australia and the United States. He has more than 35 years' experience in the securities industry with Potter Partners (now UBS), County Natwest and Citigroup. He is currently Chairman of TAL Limited (formerly Tower Australia Limited), Gragher Capital Securities and the NSW State Library. He is the immediate past non-executive Chairman of Heartware International Inc and remains a non-executive director of that company and is also a director of ASX listed REVA Medical Inc., Virgin Australia Limited and Biotron Limited. Rob holds a Bachelor of Economics from Monash University and is a fellow of the Securities Institute of Australia. He is also a Master Stockbroker and is a Fellow of the Australian Institute of Company Directors. Other current directorships of listed entities: Virgin Australia Limited, REVA Medical Inc., Biotron Limited, Heartware International Inc. (NASDAQ listed, de-listed from ASX on 17 Sep 2013) Former directorships of listed entities in last 3 years: None 270,000 ordinary shares in Starpharma Holdings Limited

Nigel Baade CFO



No fixed term of agreement. - Base salary, inclusive of superannuation, per annum as at 30 June 2014 of \$237,114, to be reviewed annually by the remuneration and nomination committee. - Subject to termination at any time by: (i) the Executive giving to the company not less than three months' written notice; or (ii) the company giving to the Executive written notice, or payment in lieu of that notice, which notice period shall be four months. - The Executive's employment may be terminated by the company at any time without notice for serious breach of obligations to the employer, wilful neglect of duty, serious misconduct or bankruptcy.

Board and Management (continued)

Peter R. Turvey **Non-Executive Director**

Mr Turvey has had more than 30 years of experience in the biotech/pharmaceutical industry having been former Executive Vice President Licensing, Group General Counsel and Company Secretary of global biopharmaceutical company CSL Limited, retiring in 2011. Mr. Turvey is currently a principal of Foursight Associates Pty Ltd, a director of the industry organisation AusBiotech Limited, and a director of Victorian Government owned entity Agriculture Victoria Services Pty Ltd. Mr. Turvey played a key role in the transformation of CSL from a government owned enterprise, through ASX listing in 1994, to a global plasma and biopharmaceutical company. He also had responsibility for the protection and licensing of CSL's intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee. Other current directorships of listed entities: Admedus Limited Former directorships of listed entities in last 3 years: None 47,000 ordinary shares in Starpharma Holdings Limited

Zita Peach **Non-Executive Director**

Ms Peach has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Ms Peach is currently the Managing Director and Executive Vice President, for Fresenius Kabi Australia and New Zealand, a leader in medical devices, intravenous fluids, intravenous genetics and clinical nutrition. Previously, Ms Peach was Vice President, Business Development R&D for CSL, a position she held for ten years. Ms Peach is a Non-Executive Director of the ASX-listed Vision Eye Institute Limited. Ms Peach is a graduate member of the Australian Institute of Company Directors. Other current directorships of listed entities: Vision Eye Institute Limited Former directorships of listed entities in last 3 years: None 3,000 ordinary shares in Starpharma Holdings Limited

Financials

Annual Report for the year ended June 30, 2014

year-on-year comparisons with previous corresponding period

Unfavourable Changes

- Total revenue down 48.5% to \$A1.3m (\$US1.2m)
- Losses in all of the last 5 years
- Current ratio down 53.5% to 7.4
- Net tangible assets per share down 30.8% to \$A0.09 (US8.3c)
- Operating cash flow is negative
- Working capital to total assets down 11.6% to 67.2%
- Total revenue to total assets down 32.2% to 0.03.


Steady

- Total debt to net tangible assets steady from 0.3% to 0.3%.

Major Common Size Ratios

- Total current assets to total assets down from 81.0% to 77.6%
- Cash to total assets down from 69.7% to 65.2%
- Total non-current assets to total assets up from 19.0% to 22.4%
- Intangibles to total assets up from 18.1% to 21.0%
- Current debtors to total assets up from 11.3% to 12.4%
- Interest expenses to sales up from 0.4% to 0.6%.

Year on Year Revenue & Net Profit



Financial Results

INCOME STATEMENT: Year-on-year Comparisons

Currency in Thousand of AUD	2014-06-30	2013-06-30	Change %
Revenue from continuing operations	1,246	2,429	Down 48.7
Other income	7	5	Up 40.0
Administration expense	-4,890	-4,149	Deterioration 17.9
Research and development expense	-10,991	-3,505	Deterioration 213.6
Finance costs	7	9	Down 22.2
Loss before income tax	-14,635	-5,229	Deterioration 179.9
Income tax expense			
Loss from continuing operations attributable to members of Starpharma Holdings Limited	-14,635	-5,229	Deterioration 179.9
Loss per share for loss from continuing operations attributable to the ordinary equity holders of the company			
Basic loss per share	-5.0c	-2.0c	Deterioration 150.0
Diluted loss per share	-5.0c	-2.0c	Deterioration 150.0
TSO	284,414,837	283,281,880	Up 0.4

BALANCE SHEET: Year-on-year Comparisons

Currency in Thousand of AUD	2014-06-30	2013-06-30	Change %
Current Assets			
Cash and cash equivalents	24,028	33,840	Down 29.0
Trade and other receivables	4,570	5,492	Down 16.8
Total Current Assets	28,598	39,332	Down 27.3
Non-Current Assets			
Property, plant and equipment	509	411	Up 23.8
Intangible assets	7,755	8,807	Down 11.9
Total Non-Current Assets	8,264	9,218	Down 10.3
Total Assets	36,862	48,550	Down 24.1
Current Liabilities			
Trade and other payables	3,114	1,696	Up 83.6
Borrowings	27	25	Up 8.0
Provisions (employee entitlements)	659	627	Up 5.1
Deferred income	44	111	Down 60.4
Total Current Liabilities	3,844	2,459	Up 56.3
Non-Current Liabilities			
Borrowings	48	75	Down 36.0
Provisions (employee entitlements)	19	48	Down 60.4
Total Non-Current Liabilities	67	123	Down 45.5
Total Liabilities	3,911	2,582	Up 51.5
Net Assets	32,951	45,968	Down 28.3

Financial Results (continued)

Equity			
Contributed equity	140,349	140,081	Up 0.2
Reserves	4,852	3,502	Up 38.5
Accumulated losses	-112,250	-97,615	Deterioration 15.0
Total Equity	32,951	45,968	Down 28.3

CASH FLOW: Year-on-year Comparisons

Currency in Thousand of AUD	2014-06-30	2013-06-30	Change %
Cash Flows from Operating Activities			
Receipts from trade and other debtors (inclusive of GST)	387	423	Down 8.5
Grant income and R&D tax incentives (inclusive of GST)	4,707	5,453	Down 13.7
Payments to suppliers and employees (inclusive of GST)	-16,108	-17,270	Reduced 6.7
Interest received	1,208	1,609	Down 24.9
Interest paid	-7	-10	Reduced 30.0
Net cash outflows from operating activities	-9,813	-9,795	Deterioration 0.2
Cash Flow from Investing Activities			
Payments for property, plant and equipment	-251	-156	Deterioration 60.9
Net cash outflows from investing activities	-251	-156	Deterioration 60.9
Cash Flow from Financing Activities			
Proceeds from issue of shares	235	878	Down 73.2
Share issue transaction costs			
Lease repayments	-32	-50	Reduced 36.0
Net cash inflows from financing activities	203	828	Down 75.5
Net increase (decrease) in cash and cash equivalents held	-9,861	-9,123	Deterioration 8.1
Cash and cash equivalents at the beginning of the year	33,840	42,812	Down 21.0
Effects of exchange rate changes on cash and cash equivalents	49	151	Down 67.5
Cash and cash equivalents at the end of the year	24,028	33,840	Down 29.0

EBITDA AND MARGINS

	2014-06-30	2013-06-30
Earnings from Cont. Ops. Margin %	-1,167.44	-214.46
Net Income Margin %	-1,168	-214.83

PERFORMANCE RATIOS

	2014-06-30	2013-06-30	Change %
Return on Assets (%)	-39.7	-10.77	Deterioration 268.6
Total debt to net tangible assets (%)	0.3	0.27	Up 10.6
Total Liabilities to Operating Cash Flow	-0.4	-0.26	Deterioration 51.2
Debt/Equity	0.002276	0.002175	Up 4.6
Total Liabilities/Total Assets	0.11	0.05	Up 99.5
Interest Cover	-2,089.71	-580	Deterioration 260.3
Current Ratio	7.44	16	Down 53.5

Financial Results (continued)

PER SHARE FIGURES

	2014-06-30	2013-06-30	Change %
Revenue from operating activities	0.44c	0.86c	Down 48.9
EBIT	-5.14c	-1.84c	Deterioration 179.1
Cash	8.45c	11.95c	Down 29.3
Working Capital	8.70c	13.02c	Down 33.1
Shareholders' Funds	11.59c	16.23c	Down 28.6
Total Liabilities	1.38c	0.91c	Up 50.9
Total Assets	12.96c	17.14c	Down 24.4
Current Debt	0.01c	0.01c	Up 7.6
Non Current Debt	0.02c	0.03c	Down 36.3
Total Debt	0.03c	0.04c	Down 25.3
Net Tangible Assets	8.86c	13.12c	Down 32.5
EPS Final	-5.0c	-2.0c	Deterioration 150.0

Glossary

Debt/Equity

Net Debt/Net Assets (times)

Current Ratio

Current Assets/Current Liabilities (times)

Interest Cover

Earnings Before Interest and Tax/Interest (times)

Return on Assets

Net Profit/Total Assets (%)

Price/NTA

Closing Share Price/Net Tangible Assets Per Share (times)

Volume Index

Number of shares traded in the period/Average number of shares traded for the period

Moving Average Price (n periods)

Sum of Prices for each Period/Number of Periods

Price Close/Moving Av Price

Latest Price/Moving Average Price

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews “hot tip” or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

Further details on definitions and quotations from investing legends can be found in following link: <http://buysellsignals.com/PressClipping/DefinationOfVariable.php>.

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
